Abstract:Over the last decade, hydrogen sulfide (H2S) has emerged as an important endogenous gasotransmitter in mammalian cells and tissues. Similar to the previously characterized gasotransmitters nitric oxide and carbon monoxide, H2S is produced by various enzymatic reactions and regulates a host of physiologic and pathophysiological processes in various cells and tissues. H2S levels are decreased in a number of conditions (e.g., diabetes mellitus, ischemia, and aging) and are increased in other states (e.g., inflammation, critical illness, and cancer). Over the last decades, multiple approaches have been identified for the therapeutic exploitation of H2S, either based on H2S donation or inhibition of H2S biosynthesis. H2S donation can be achieved through the inhalation of H2S gas and/or the parenteral or enteral administration of so-called fast-releasing H2S donors (salts of H2S such as NaHS and Na2S) or slow-releasing H2S donors (GYY4137 being the prototypical compound used in hundreds of studies in vitro and in vivo). Recent work also identifies various donors with regulated H2S release profiles, including oxidant-triggered donors, pH-dependent donors, esterase-activated donors, and organelle-targeted (e.g., mitochondrial) compounds. There are also approaches where existing, clinically approved drugs of various classes (e.g., nonsteroidal anti-inflammatories) are coupled with H2S-donating groups (the most advanced compound in clinical trials is ATB-346, an H2S-donating derivative of the non-steroidal anti-inflammatory compound naproxen). For pharmacological inhibition of H2S synthesis, there are now several small molecule compounds targeting each of the three H2S-producing enzymes cystathionine-β-synthase (CBS), cystathionine-γ-lyase, and 3-mercaptopyruvate sulfurtransferase. Although many of these compounds have their limitations (potency, selectivity), these molecules, especially in combination with genetic approaches, can be instrumental for the delineation of the biologic processes involving endogenous H2S production. Moreover, some of these compounds (e.g., cell-permeable prodrugs of the CBS inhibitor aminooxyacetate, or benserazide, a potentially repurposable CBS inhibitor) may serve as starting points for future clinical translation. The present article overviews the currently known H2S donors and H2S biosynthesis inhibitors, delineates their mode of action, and offers examples for their biologic effects and potential therapeutic utility.

Hydrosulfide-methaemoglobin-albumin cluster: A hydrogen sulfide donor

Hydrogen Sulfide as a Potential Therapeutic Target in Fibrosis

A Long-Term and Slow-Releasing Hydrogen Sulfide Donor Protects Against Myocardial Ischemia/Reperfusion Injury

[Effect of Synthesized GYY4137, a Slowly Releasing Hydrogen Sulfide Donor, on Cell Viability and Distribution of Hydrogen Sulfide in Mice].

Controlled-releasing hydrogen sulfide donor based on dual-modal iron oxide nanoparticles protects myocardial tissue from ischemia-reperfusion injury.

Erythrocyte Membrane Coated Nanoparticle-Based Control Releasing Hydrogen Sulfide System Protects Ischemic Myocardium.

Controlled Release Hydrogen Sulfide Delivery System Based on Mesoporous Silica Nanoparticles Protects Graft Endothelium from Ischemia-Reperfusion Injury.

Hydrogen Sulfide Attenuates the Recruitment of CD11b + Gr-1 + Myeloid Cells and Regulates Bax/Bcl-2 Signaling in Myocardial Ischemia Injury

A ROS-responsive, self-immolative and self-reporting hydrogen sulfide donor with multiple biological activities for the treatment of myocardial infarction

Protective Effects Of Hydrogen Sulfide In Hypoxic Human Umbilical Vein Endothelial Cells: A Possible Mitochondria-Dependent Pathway

Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice

Abstract 10189: A Novel Hypothermia-Triggered and Controlled-Release Hydrogen Sulfide Delivery System Exerts Myocardial Protection from Ischemia-Reperfusion Injury

Sodium thiosulfate: A donor or carrier signaling molecule for hydrogen sulfide?

International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors

Hydrogen Sulfide and Translational Medicine

Hydrogen Sulfide Attenuates Carbon Tetrachloride-Induced Hepatotoxicity, Liver Cirrhosis and Portal Hypertension in Rats

Hydrogen Sulfide Inhibits Myocardial Injury Induced by Homocysteine in Rats

Sodium Hydrosulfide Protects Rats from Hypobaric-Hypoxia-Induced Acute Lung Injury

Therapeutic Potential of Hydrogen Sulfide in Ischemia and Reperfusion Injury

Development of hydrogen sulfide donors for anti-atherosclerosis therapeutics research: Challenges and future priorities

Sodium Hydrosulfide Prevents Myocardial Dysfunction Through Modulation of Extracellular Matrix Accumulation and Vascular Density